强化短程方案与标准方案治疗成人结核性脑膜炎的比较评价:INSHORT试验——一项开放标签、多中心、平行组、随机对照优效性试验方案
该方案拟在印度6个中心纳入372例结核性脑膜炎成人患者,按1:1:1随机分为三组:高剂量利福平(25 mg/kg)联合莫西沙星、吡嗪酰胺、异烟肼、阿司匹林(150 mg)及激素治疗2个月后继续利福平、异烟肼、吡嗪酰胺4个月;第二干预组除阿司匹林外同第一组;对照组按国家结核病消除规划指南治疗。所有患者治疗后随访1年,主要评价无残疾生存。
要点
- 方案纳入372例成人结核性脑膜炎患者,在印度6个中心按1:1:1随机分组。
- 干预组含高剂量利福平(25 mg/kg)、莫西沙星(400 mg)、阿司匹林(150 mg)及激素,疗程共6个月。
- 对照组按国家结核病消除规划指南治疗,所有患者治疗后随访1年。
核心结论
- 作者提出一项综合临床试验,整合近二十年结核性脑膜炎领域的新证据,以缩短疗程并改善治疗结局,该多中心试验可能产生对结核性脑膜炎治疗具有政策和实践意义的关键证据。
研究设计与样本
- 开放标签、平行组、随机对照优效性试验,在印度6个中心纳入372例符合条件的参与者,按1:1:1随机分配至三个组。
主要发现
- 第一干预组接受高剂量利福平(25 mg/kg)、莫西沙星(400 mg)、吡嗪酰胺、异烟肼、阿司匹林(150 mg)及激素治疗2个月,随后接受利福平、异烟肼和吡嗪酰胺治疗4个月。
- 第二干预组接受除阿司匹林外的第一干预组全部药物。
- 对照组按国家结核病消除规划指南接受治疗。
- 所有参与者治疗后随访1年。
关键数值与推荐
- 第一干预组:高剂量利福平25 mg/kg、莫西沙星400 mg、阿司匹林150 mg,联合吡嗪酰胺、异烟肼及激素治疗2个月,随后利福平、异烟肼、吡嗪酰胺治疗4个月。
- 第二干预组:除阿司匹林外,药物同第一干预组。
- 对照组:按国家结核病消除规划指南治疗。
临床怎么用
- 作者认为该多中心试验可能产生对结核性脑膜炎治疗具有政策和实践意义的关键证据。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite several incremental improvements in the management of tuberculous meningitis (TBM), the mortality rates remain high. In spite of national and international guidelines, variation in the choice, dose, and duration of drugs exist between countries and clinicians. We propose to evaluate a shorter and more effective regimen containing agents with augmented intracerebral drug exposure and anti-inflammatory approaches to improve disability-free survival among patients with TBM. Our strategy incorporates the various developments in the field of TBM over the last two decades and only few trials have evaluated a composite of these strategies in the overall outcomes of TBM. METHODS: An open label, parallel arms, randomized controlled superiority trial will be conducted among 372 participants across 6 sites in India. Eligible participants will be randomly allocated in 1:1:1 ratio into one of the three arms. The intervention arm consists of 2 months of high-dose rifampicin (25 mg/kg), moxifloxacin (400 mg), pyrazinamide, isoniazid, aspirin (150 mg), and steroids followed by rifampicin, isoniazid, and pyrazinamide for 4 months. The second intervention arm includes all the drugs as per the first arm except aspirin and the patients in the control arm will receive treatment according to the National TB Elimination Program guidelines. All participants will be followed up for 1 year after the treatment. DISCUSSION: Current WHO regimens have agents with poor central nervous system drug exposure and is too long. It does not reflect the accumulating evidence in the field. We propose a comprehensive clinical trial incorporating the emerging evidence accrued over the last two decades to shorten the duration and improve the treatment outcomes. This multi-centric trial may generate crucial evidence with policy and practice implications in the treatment of TBM. TRIAL REGISTRATION: Clinical Trial Registry India CTRI/2023/05/053314. Registered on 31 May 2023 ( https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=ODYzMzg=&Enc=&userName=CTRI/2023/05/053314 ). CLINICALTRIALS: gov NCT05917340. Registered on 6 August 2023 ( https://classic. CLINICALTRIALS: gov/ct2/show/NCT05917340 ). PROTOCOL VERSION: Version 1.3 dated 12 July 2023.
引用
- Inbaraj LR, Manesh A, Ponnuraja C, et al. Comparative evaluation of intensified short course regimen and standard regimen for adults TB meningitis: a protocol for an open label, multi-center, parallel arms, randomized controlled superiority trial (INSHORT trial). Trials. 2024. PMID: 38693583. doi:10.1186/s13063-024-08133-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。